Please assess the completion status of the following clinical trial:

Trial Title: Effects of Tetrahydrobiopterin on Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients without childbearing potential between the ages of 18 and 75 years~2. History of documented essential hypertension or newly diagnosed hypertension (BP \>140 mmHg systolic and/or 90 mmHg diastolic measured on 2 separate occasions)~3. Patients on conventional anti-hypertensive therapy with poorly controlled hypertension (BP \>135/85 mmHg). Their anti-hypertensive regimen will remain unchanged throughout the study period. Patients will not need to stop taking their prescribed anti-hypertensives.~4. Controls will be recruited for part 2 of the study. These will be patients who meet the age and childbearing criteria above, who have no history of hypertension, arterial BP of \<130 systolic and \<85 diastolic, no evidence of diabetes mellitus, total cholesterol \<240 and be non-smoking for at least six months.~5. Patients can be at any stage of hypertension. They can be at any performance status. The only requirement will be that they be able to come to scheduled follow up visits either by themselves or with assistance. Patients will need to be able to give informed consent.~Exclusion Criteria:~1. Female subjects with childbearing potential.~2. History of symptomatic coronary or peripheral vascular disease.~3. Known secondary causes for hypertension~4. Severe uncontrolled hypertension (BP \>180 mmHg systolic and /or 110 mmHg diastolic).~5. Severe co-morbid conditions which would limit life expectancy to less than 6 months.~6. Patients unable to give informed consent or adhere to the protocol.~7. Patients participating in another study protocol.~8. Patients with organ failure, creatinine \>2.5 mg/dL or hepatic enzymes \>2X normal~9. Recent (within 6 weeks) alteration of any concomitant therapy.~10. Presence of intercurrent illness~11. Bleeding disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dose-response of oral BH4 (Type: EXPERIMENTAL): Eight subjects received 100 mg of oral BH4 twice a day and 8 received 200 mg twice daily.
- Onset & duration of action of oral BH4 (Type: EXPERIMENTAL): Eight hypertensive subjects were assigned to either 5 mg kg-1 day-1 (n=4) or 10 mg kg-1 day-1 (n=4) of BH4, given in two divided doses orally for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).